Literature DB >> 12441358

A single mutation in the 5-HT4 receptor (5-HT4-R D100(3.32)A) generates a Gs-coupled receptor activated exclusively by synthetic ligands (RASSL).

Sylvie Claeysen1, Lara Joubert, Michèle Sebben, Joël Bockaert, Aline Dumuis.   

Abstract

To better understand G-protein-coupled receptor (GPCRs) signaling, cellular and animal physiology, as well as gene therapy, a new tool has recently been proposed. It consists of GPCR mutants that are insensitive to endogenous ligands but sensitive to synthetic ligands. These GPCRs are called receptor activated solely by synthetic ligands (RASSL). Only two examples of such engineered receptors have been described so far: one G(i)-coupled (opioid receptors) and one G(s)-coupled (beta(2)-adrenergic receptors). Here, we describe the first RASSL related to serotonin receptors (D100(3.32)A G(s)-coupled 5-HT(4) receptor or 5-HT(4)-RASSL). 5-HT(4)-RASSL is generated by a single mutation, is totally insensitive to serotonin (5-HT), and still responds to synthetic ligands. These ligands have affinities in the range of nanomolar concentrations for the mutant receptor and exhibit full efficacy. More interestingly, two synthetic ligands behave as antagonists on the wild type but as agonists on the 5-HT(4)-RASSL.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12441358     DOI: 10.1074/jbc.C200588200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  26 in total

1.  Engineering a GPCR-ligand pair that simulates the activation of D(2L) by Dopamine.

Authors:  Nuska Tschammer; Miriam Dörfler; Harald Hübner; Peter Gmeiner
Journal:  ACS Chem Neurosci       Date:  2009-09-24       Impact factor: 4.418

Review 2.  The congenital muscular dystrophies: recent advances and molecular insights.

Authors:  Jerry R Mendell; Daniel R Boué; Paul T Martin
Journal:  Pediatr Dev Pathol       Date:  2006 Nov-Dec

3.  Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand.

Authors:  Blaine N Armbruster; Xiang Li; Mark H Pausch; Stefan Herlitze; Bryan L Roth
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-02       Impact factor: 11.205

4.  New tools to build synthetic hormonal pathways.

Authors:  Bruce R Conklin
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-12       Impact factor: 11.205

5.  G protein activation by serotonin type 4 receptor dimers: evidence that turning on two protomers is more efficient.

Authors:  Lucie P Pellissier; Gaël Barthet; Florence Gaven; Elisabeth Cassier; Eric Trinquet; Jean-Philippe Pin; Philippe Marin; Aline Dumuis; Joël Bockaert; Jean-Louis Banères; Sylvie Claeysen
Journal:  J Biol Chem       Date:  2011-01-19       Impact factor: 5.157

Review 6.  Remote control of neuronal signaling.

Authors:  Sarah C Rogan; Bryan L Roth
Journal:  Pharmacol Rev       Date:  2011-03-17       Impact factor: 25.468

Review 7.  Structure and function of serotonin G protein-coupled receptors.

Authors:  John D McCorvy; Bryan L Roth
Journal:  Pharmacol Ther       Date:  2015-01-17       Impact factor: 12.310

8.  Ligand modulation of the Epstein-Barr virus-induced seven-transmembrane receptor EBI2: identification of a potent and efficacious inverse agonist.

Authors:  Tau Benned-Jensen; Christopher Smethurst; Peter J Holst; Kevin R Page; Howard Sauls; Bjørn Sivertsen; Thue W Schwartz; Andy Blanchard; Robert Jepras; Mette M Rosenkilde
Journal:  J Biol Chem       Date:  2011-06-14       Impact factor: 5.157

Review 9.  Engineering GPCR signaling pathways with RASSLs.

Authors:  Bruce R Conklin; Edward C Hsiao; Sylvie Claeysen; Aline Dumuis; Supriya Srinivasan; John R Forsayeth; Jean-Marc Guettier; W C Chang; Ying Pei; Ken D McCarthy; Robert A Nissenson; Jürgen Wess; Joël Bockaert; Bryan L Roth
Journal:  Nat Methods       Date:  2008-08       Impact factor: 28.547

10.  Engineered G-protein Coupled Receptors are Powerful Tools to Investigate Biological Processes and Behaviors.

Authors:  Charles D Nichols; Bryan L Roth
Journal:  Front Mol Neurosci       Date:  2009-10-23       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.